658: SUCCESSFUL TREATMENT OF LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE IN A PATIENT WITH HEMOPHILIA A

Background. Acquired hemophilia A (AHA) is a rare condition, due to the spontaneous formation of neutralizing antibodies against endogenous factor VIII. About half the cases are associated with pregnancy, postpartum, autoimmune diseases, malignancies, or adverse drug reactions. Symptoms include severe and unexpected bleeding that may prove life-threatening.Case Study. We report a case of AHA associated with bullous pemphigoid (BP), a chronic, autoimmune, subepidermal, blistering skin disease. To our knowledge, this is the 25th documented case of such an association. Following treatment for less than 3 months consisting of methylprednisolone at decreasing dose levels along with four courses of rituximab (monoclonal antibody directed against the CD20 protein), AHA was completely cured and BP well-controlled.Conclusions. This report illustrates a rare association of AHA and BP, supporting the possibility of eradicating the inhibitor with a well-conducted short-term treatment.

Download Full-text

Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit

Intensive Care Medicine ◽

10.1007/s00134-011-2258-5 ◽

2011 ◽

Vol 37 (8) ◽

pp. 1240-1249 ◽

Cited By ~ 12

Author(s):

Aryeh Shander ◽

Christopher E. Walsh ◽

Caroline Cromwell

Keyword(s):

Intensive Care Unit ◽

Intensive Care ◽

Hemophilia A ◽

Acquired Hemophilia A ◽

Acquired Hemophilia ◽

Life Threatening

Download Full-text

Use of recombinant activated factor VII

Medicina ◽

10.3390/medicina45030032 ◽

2009 ◽

Vol 45 (3) ◽

pp. 248

Author(s):

Dagmara Reingardienė ◽

Robertas Lažauskas

Keyword(s):

Prothrombin Time ◽

Liver Diseases ◽

Hemophilia A ◽

Tissue Injury ◽

Factor Vii ◽

Recombinant Activated Factor Vii ◽

Congenital Deficiency ◽

Activated Factor Vii ◽

Life Threatening ◽

Hemostatic Disorders

Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and acquired hemostatic disorders for more than 10 years. Hemostasis is initiated by the FVIIa bound to tissue factor (TF), which constitutes only approximately 1% of total amount of the FVII protein existing in the blood. rFVII becomes activated only after the binding to the TF, released at the site of tissue injury. The efficiency of rFVIIa in the treatment of such life-threatening hemorrhagic states like hemophilia reaches up to 76–84%. rFVIIa is successfully used in the treatment of congenital deficiency of factor VII. It normalizes prothrombin time in the patients with the liver diseases and in cases of overdose of indirect anticoagulants. It is also useful for patients suffering from thrombocytopenia, thrombocyte function disorders, hemophilia A and B with development of inhibitors. rFVIIa allows overcoming uncontrollable hemorrhages, etc. It is supposed that rFVIIa is becoming a universal hemostatic drug.

Download Full-text

Successful treatment of false aneurysm of the subclavian artery

Grekov s Bulletin of Surgery ◽

10.24884/0042-4625-2019-178-2-69-72 ◽

2019 ◽

Vol 178 (2) ◽

pp. 69-72

Author(s):

A. N. Ryazanov ◽

V. V. Soroka ◽

S. P. Nokhrin ◽

E. P. Mikhelson ◽

I. D. Magamedov ◽

...

Keyword(s):

Postoperative Complications ◽

Minimally Invasive ◽

Positive Result ◽

Subclavian Artery ◽

Successful Treatment ◽

New Technologies ◽

False Aneurysm ◽

Life Threatening ◽

Minimally Invasive Methods

The article describes the clinical experience of treatment of life-threatening pathology by minimally invasive methods. There is a long-term stable positive result after the operation. The introduction of new technologies in medicine minimizes the risk of postoperative complications, contributing to a favorable outcome of the disease.

Download Full-text